Monument Therapeutics Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for Schizophrenia

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

MONUMENT-THERAPEUTICS

More Like This

PR Newswire associated0

Monument Therapeutics Launches First Clinical Study of MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia

PR Newswire associated0

Monument Therapeutics Secures £1M Investment to Fund Its Schizophrenia Programme And Drive Next Stage of Growth

PR Newswire associated0

Monument Therapeutics Announces Grant of UK Patent for Neuroinflammation Compound MT1980

PR Newswire associated0

Monument Therapeutics Announces Appointment of Dr Stephen Brannan, Dr Jeff Baker and Dr Mark Treherne to its Advisory Board to Guide Schizophrenia Program

PR Newswire associated0

Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board

Professor Claude Wischik (Photo: Business Wire)

TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March

Business Wire logo

TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease

ACCESSWIRE associated0

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project